Advertisement

Topics

Suzhou Alphamab Co., Ltd. Company Profile

18:20 EDT 17th October 2018 | BioPortfolio

Alphamab, founded in 2009, is a leading biotechnology company focused on the discovery and development of innovative biologics therapeutics. With multiple in-house proprietary platforms in protein engineering, antibody screening and bispecifics, Alphamab and its subsidiaries have created a robust pipeline of over 20 innovative biologics programs in oncology and several other areas. Alphamab is striving to develop 1st-in-class or best-in-class medicine to address unmet medical needs globally.


News Articles [80 Associated News Articles listed on BioPortfolio]

Suzhou Alphamab to Start China Trial of Bispecific HER2 Inhibitor

Suzhou Alphamab was granted CFDA approval of an IND for its leading bispecific program, a HER2 inhibitor, which will be tested in patients with HER2 positive breast and gastric cancers. According to A...

Alphamab Starts Australian Trial of PD-L1/CTLA-4 Bispecific

Alphamab Oncology of Suzhou has started a Phase I clinical trial of its humanized PD-L1/CTLA-4 bispecific antibody in Australia. The company has also been approved to conduct a similar China trial of ...

Alphamab’s Novel Her-2 Bispecific Antibody KN026 Gains IND Approval in China; CMC Validation of Its Proprietary Bispecific Platform

Suzhou Alphamab Co., Ltd. announced today that the IND for its leading bispecific program KN026 has been approved by the CFDA, marking a significant milestone for Alphamab in deve...

Alphamab Oncology's HER2 bispecific antibody KN026 gained US IND approval; phase I clinical trial started in China

SUZHOU, China, Oct. 16, 2018 /PRNewswire/ -- Alphamab Oncology announced that it has received US FDA's IND approval for its proprietary HER2 bispecific antibody (product code: KN026), and KN026 i...

Alphamab Oncology's first-in-class PD-L1 - CTLA-4 bispecific antibody enters clinical trial

SUZHOU, China, Oct. 10, 2018 /PRNewswire/ -- Alphamab Oncology announced that its proprietary humanized PD-L1 - CTLA-4 bispecific antibody (product code: KN046) program, the first of its class, has re...

Alphamab's HER2 bispecific antibody to enter clinic in China

Alphamab's bispecific checkpoint antibody enters clinic in Australia, Chinese trials planned

Week in Review: Biosense Exercises $75 Million Option for China Rights to Neovacs' Lupus Immunotherapy

Deals and Financings  Biosense Global, a New Jersey-Suzhou company, exercised a $75 million option for China rights to a lupus immunotherapy developed by Neovacs of France; Daiichi Sankyo acquir...

PubMed Articles [14 Associated PubMed Articles listed on BioPortfolio]

The Fifth Influenza A(H7N9) Epidemic: A Family Cluster of Infection in Suzhou City of China, 2016.

Influenza A(H7N9) virus is known for its high pathogenicity in human. A family cluster of influenza A(H7N9) virus infection was identified in Suzhou, China. This study aimed to investigate the possibi...

Contamination Characterization and Human Exposure Levels to Polybrominated Diphenyl Ethers in Indoor and Outdoor Air in Industrial Park of Suzhou City.

Eight polybrominated diphenyl ether (PBDE) congeners in indoor and outdoor air particles were collected using higher-volume active sampling techniques from different functional areas, including an ind...

Contamination Characteristics and Human Exposure to Organophosphate Flame Retardants in Road Dust from Suzhou City.

The contamination levels and distribution characteristics of four organophosphate flame retardants (OPFRs) in 25 outdoor dust samples collected in Suzhou were quantitatively analyzed by gas chromatogr...

Influenza-Associated Hospitalization in Children Younger Than Five Years of Age in Suzhou, China, 2011- 2016.

Studying the burden and risk factors associated with severe illness from influenza infection in young children in eastern China will contribute to future cost-effectiveness analyses of local influenza...

Risk Factors for Severe Community-Acquired Pneumonia Among Children Hospitalized with CAP Younger Than 5 Years of Age.

CAP causes great morbidity and mortality as well as enormous economic burden worldwide. This study intended to describe the clinical characteristics of CAP and explore the risk factors of severe CAP a...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Deep Brain Stimulation of Nucleus Accumbens for Opioid Relapse Prevention

Nucleus accumbens plays important roles in the process of opiate addiction and initial of relapse after detoxification.According to the single-centered preliminary open-labeled prospective...

Companies [18 Associated Companies listed on BioPortfolio]

Suzhou Alphamab Co., Ltd.

Alphamab, founded in 2009, is a leading biotechnology company focused on the discovery and development of innovative biologics therapeutics. With multiple in-house proprietary pla...

SINOCHEM JIANGSU SUZHOU I/E CORP.

SINOCHEM JIANGSU SUZHOU I/E CORP. ESTABLISHED IN 1988, IS A SUBSIDIARY OF SINOCHEM AND A STATE-OWNED FOREIGH TRADE ENTERPRISE AUTHORISED BY THE CHINESE MINISTRY OF FOREIGH TRADE AND ECONOMIC C...

Suzhou Kaiyuan Minsheng Chemicals Technology Co.,Ltd

Suzhou Kaiyuan Minsheng Chemicals Technology Co., Ltd.(briefed as MSTC)is located in Sino-Singapore Suzhou Industrial Park, covering an area of 37,500 square meters excluding the factories. Integratin...

Suzhou No.5 Pharmaceutical Factory Co., Ltd.

Suzhou No.5 Pharmaceutical Factory was founded in 1962 for the production of API's and API intermediates. During the past 40 years the Company firmly established a strong presence in the pharmaceutica...

Dawnrays Pharmaceutical (Holdings) Ltd.

Dawnrays Pharmaceutical (Holdings) Ltd., founded on 8th December 1995 by a Hong Kong investor, is now being the parent company as a listed company in Hong Kong Stock Exchange Market since 7th Novembe...

More Information about "Suzhou Alphamab Co., Ltd." on BioPortfolio

We have published hundreds of Suzhou Alphamab Co., Ltd. news stories on BioPortfolio along with dozens of Suzhou Alphamab Co., Ltd. Clinical Trials and PubMed Articles about Suzhou Alphamab Co., Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Suzhou Alphamab Co., Ltd. Companies in our database. You can also find out about relevant Suzhou Alphamab Co., Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record